# DESCRIPTION

## FIELD OF THE INVENTION

- introduce California encephalitis group of Bunyaviruses

## DESCRIPTION OF THE RELATED ART

- describe La Crosse virus (LACV) and its effects
- discuss LACV's life cycle and transmission

## SUMMARY OF THE INVENTION

- identify nucleotide sequences associated with wild type LACV phenotype
- describe mutations affecting LACV neuroinvasiveness
- outline development of live attenuated virus vaccine
- summarize subunit vaccine compositions and immunogenic compositions
- describe methods of treating and preventing CEV serogroup infection

## BRIEF DESCRIPTION OF THE APPENDICES

- list appendices containing genomic segment-nucleotide and amino acid sequence alignments

## DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

### Definitions

- define technical and scientific terms
- explain transitional terms
- define polypeptide and protein
- describe CEV serogroup polypeptide
- define analog and mutein
- explain fragment of polypeptide
- define M polypeptide
- describe antigen and immunogen
- define epitope
- explain immunological response
- define subunit vaccine
- define polynucleotide derived from a designated sequence
- define coding sequence and its boundaries
- define operably linked elements
- define recombinant nucleic acid molecule and protein
- define control elements and their functions
- define expression cassette and its components
- define transformation and nucleic acid immunization
- define various terms related to antibodies, solid supports, and immunological reactions

### Bunyaviridae Viruses

- describe Bunyaviridae viruses and their characteristics

### CEV Subgroup Polypeptides and Polynucleotides

- describe CEV serogroup polypeptides and polynucleotides
- discuss immunogens for use in subunit vaccines and diagnostics
- describe methods for obtaining polynucleotides and polypeptides
- discuss modification of sequences encoding polypeptides of interest
- describe expression of polypeptides in various systems
- discuss production and purification of polypeptides

### Inactivated CEV Serogroup Vaccines

- describe inactivated CEV serogroup vaccines and methods for production

### Attenuated CEV Serogroup Vaccines

- describe attenuated CEV serogroup vaccines and methods for production
- discuss methods for attenuating viruses, including serial passage and mutagenesis

### Compositions Comprising CEV Serogroup, Polypeptides, and Polynucleotides

- describe composition components
- list pharmaceutically acceptable carriers and adjuvants

### Administration

- describe administration methods
- provide examples of formulations and delivery systems
- discuss dosage and treatment schedules
- explain gene delivery protocols

### CEV Serogroup Antibodies

- describe production of polyclonal and monoclonal antibodies
- discuss uses of antibodies in diagnostic and therapeutic applications

### CEV Serogroup Diagnostic Assays

- describe protein assays
- list solid supports for assays
- outline ELISA method
- detail competitive-type ELISA techniques
- describe assays in solution
- outline immunoaffinity matrix method
- describe kit composition
- outline nucleic acid-based assays
- describe probe-based assays
- outline PCR-based techniques
- describe fluorogenic 5â€² nuclease assay
- introduce CEV serogroup diagnostic assays
- describe chimeric Bunyaviridae construction
- define counterpart genes and gene segments
- explain sequence identity and similarity
- discuss conservative amino acid substitutions
- describe cDNA-based methods for constructing chimeric Bunyaviridae
- introduce attenuating point mutations
- describe biologically-derived Bunyaviridae family members
- explain methods for producing attenuated Bunyaviridae family members
- discuss incorporation of attenuating point mutations into chimeric Bunyaviridae
- describe site-specific mutations
- explain deletions, insertions, substitutions, or rearrangements of whole genes or gene segments
- discuss additional methods for attenuating chimeric Bunyaviridae
- introduce CEV serogroup diagnostic assays
- describe chimeric Bunyaviridae with ablated gene expression
- outline methods for producing attenuated vaccine viruses
- discuss insertion of foreign genes or gene segments into chimeric Bunyaviridae genome
- describe deletions, insertions, substitutions, and other mutations in chimeric Bunyaviridae
- introduce compositions for producing isolated infectious chimeric Bunyaviridae
- outline methods for introducing defined mutations into infectious Bunyaviridae
- describe production of infectious Bunyaviridae from cDNA-expressed genome
- discuss selection of candidate chimeric vaccine viruses
- outline testing of attenuated chimeric viruses in vitro and in vivo
- describe isolated, infectious chimeric Bunyaviridae compositions for vaccine use
- outline administration of vaccine and immunogenic compositions to hosts
- introduce CEV serogroup diagnostic assays
- describe LACV growth kinetics
- determine LD50 of LACV in mice
- define panel of LACV genomic sequences
- identify host-specific sequences
- establish murine model of LACV infection
- describe mutations attenuating LACV
- detail methods for cells and viruses
- outline sequence analysis of viral genomes

